

In the Claims:

Please cancel claims 2-3, 8-14 and 16-21 without prejudice or disclaimer.

1. (Reiterated) A process for preparing a biologically active fraction AHD04 from a composition of *Hedyotis Diffusae* comprising extracting a fraction having an optical absorbance between about 210 nm and about 250 nm.

2. (Cancelled) A process for preparing a biologically active fraction EHDA from a composition of *Hedyotis Diffusae*, comprising the steps of steeping an effective amount of *Hedyotis Diffusae* in an effective amount of hot water to obtain a liquid extract and filtering the extract to obtain EHDA.

3. (Cancelled) The process of claim 1, comprising the steps of:

(a) Steeping an effective amount of *Hedyotis Diffusae* in hot water to obtain a liquid extract;

(b) Centrifuging to obtain a clear liquid extract;

(c) Drying the liquid extract and resuspending in an acceptable carrier; and

(d) Obtaining the action fraction by chromatography to obtain a biologically active extract AHD04 having an optical absorbance from about 210 nm to about 250 nm.

4. (Reiterated) A biologically active extract obtained by the process of any of claims 1.

5. (Reiterated) A composition comprising the extract of claim 4 and a pharmaceutically acceptable carrier.

6. (Reiterated) The composition of claim 1, further comprising an effective amount of an agent selected from the group consisting of anti-angiogenic, anti-tumor and immune enhancing.

7. (Reiterated) A method for inhibiting the growth of endothelial cells, comprising delivering to the cells a growth inhibitory amount of the extract of claim 4.

8. (Cancelled) A method of inhibiting vascularization in a tissue, comprising delivering to the tissue an anti-vascularization amount of the extract of claim 4.

9. (Cancelled) A method of treating a disorder associated with pathological neovascularization in a subject, comprising administering to a subject a therapeutically effective amount of the extract of claim 4.

10. (Cancelled) The method of claim 9, wherein the disorder is selected from the group consisting of cancer, arthritic conditions, neovascular-based dermatological conditions,

diabetic retinopathy, restenosis, Kaposi's Sarcoma, age-related macular degeneration, telangiectasia, glaucoma, keloids, corneal graft rejection, wound granularization, angiofibroma, Osler-Webber Syndrome, myocardial angiogenesis, and scleroderma.

11. (Cancelled)The method of claim 10, wherein the disorder is an arthritic condition selected from the group consisting of rheumatoid arthritis, psoriatic arthritis and osteoarthritis.

12.(Cancelled)The method of claim 10, wherein the delivering is by oral administration, intravenous, intraperitoneal, or transdermal.

13. (Cancelled)The method of claim 9, wherein the subject is an animal.

14. (Cancelled)The method of claim 13, wherein the animal is selected from the group consisting of a pet, a farm animal or a human patient.

15. (Amended)The method of ~~any one~~ claims 7, ~~8 or 9~~, further comprising administering to the subject an effective amount of an agent selected from the group consisting of anti-angiogenic, anti-tumor or immune enhancing.

16. (Cancelled)A method for screening for a therapeutic agent for inhibiting neovascularization or endothelial cell growth comprising the steps of:

(a) Contacting the agent with a suitable cell or tissue sample;

(b) Contacting a separate sample of the suitable cell or tissue sample with a therapeutically effective amount of an extract of claim 4; and

(c) Comparing the growth of the sample of step (a) with the growth of the sample of step (b), and wherein any agent of step (a) that inhibits the growth to the same or similar extent as the sample of step (b) is a therapeutic agent for inhibiting neovascularization or the growth of endothelial cells.

17. (Cancelled)The method of claim 16, wherein the contacting is *in vitro* or *in vivo*.

18. (Cancelled)The method of claim 16, further comprising contacting the samples of step (b) with an agent selected from the group consisting of anti-angiogenic, anti-tumor and immune enhancing.

19. (Cancelled)A kit for treating a disorder associated with pathological neovascularization in a host, comprising a therapeutically effective amount of the extract of claim 4 and instructions for use.

20. (Cancelled)The kit of claim 19, wherein the disorder is selected from the group consisting of cancer, arthritic conditions, neovascular-based dermatological conditions, diabetic retinopathy, Kaposi's Sarcoma, age-related macular degeneration, restenosis, telangiectasia, glaucoma, keloids, corneal graft rejection, wound granularization, angiofibroma,

Osler-Webber Syndrome, myocardial angiogenesis, and scleroderma.

21. (Cancelled)The kit of claim 20, wherein the disorder is an arthritic condition selected from the group consisting of rheumatoid arthritis, psoriatic arthritis and osteoarthritis.